Clinical trial
Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In…
NCT00137020 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00137020 |
|---|---|
| Title | Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder |
| Official title | A Multi-Center Study to Examine The Clinical Effects of Cross Titration of Antipsychotics With Ziprasidone in Subjects With Schizophrenia or Schizoaffective Disorder |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia, Psychotic Disorders |
| Intervention type | Drug |
| Interventions | ziprasidone |
| Enrollment | 294 |
| Start date | Nov 1, 2004 |
| Completion | Apr 1, 2006 |
| First posted | Aug 29, 2005 |
| Last update posted | Feb 21, 2021 |
| Countries | Egypt, Greece, Jordan, Kuwait, Lebanon, Saudi Arabia, South Africa, Turkey (Türkiye), United Arab Emirates |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: